CClinicalTrials.gg
RecruitingNCT07191327PCAUpdated Jun 30, 2026

Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy

An interventional study of HD-tDCS sessions and Sham HD-tDCS sessions in Posterior Cortical Atrophy, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This study is being completed to learn if high-definition transcranial direct current stimulation (HD-tDCS) has an effect on visual and thinking abilities in persons with posterior cortical atrophy (PCA). Participants will be randomized to receive real or sham HD-tDCS (8 sessions over 4 days).

Following the randomized treatment, participants will have optional open-label phase with real HD-tDCS up to 26 weeks and other possible testing.

02

Conditions studied

  • Posterior Cortical Atrophy

Keywords

  • HD-tDCS
  • Functional Magnetic resonance imaging (fMRI)
  • Positron emission tomography/computerized tomography
  • Memory and thinking testing
  • Computerized tests
  • Questionnaires
  • Blood draws
  • Eye tracking and vision tests
  • Functional Near Infrared Spectroscopy
03

In context

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis or symptoms consistent with PCA
  • Fluent in English
  • HD-tDCS compatible
  • Stable on relevant medications for at least approximately 4 weeks prior to study enrollment
  • If completing any additional, optional, long-term study visits in a remote location (i.e., not our office), a study partner is required in order to administer HD-tDCS. Those choosing to return to our office may have, but are not required to have, a study partner.

Exclusion criteria

Exclusion Criteria:

  • Other relevant neurological disease (e.g., epilepsy) or injuries (e.g., large vessel stroke, moderate-severe traumatic brain injury) viewed as primary to deficits since these could interfere with etiologic considerations and confound study results
  • Active, relevant psychiatric conditions (e.g., bipolar disorder, schizophrenia) since the symptoms of these conditions may confound study participation.
  • A recent (e.g., within the past 2 years) significant history of, or current, alcohol or drug abuse/dependence. Remote history of abuse/dependence is not exclusionary as long as it is not considered to be the primary etiology for visuospatial deficits.
  • Women that are lactating/breastfeeding, pregnant, or may potentially be pregnant will be excluded from the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Real stimulation - Randomized

    Four consecutive days (2 sessions for 20 minutes each day for a total of 8 sessions) of this blinded stimulation.

    Device: HD-tDCS sessions

  • Sham comparator
    Sham stimulation - Randomized

    Four consecutive days (2 sessions for 20 minutes each day for a total of 8 sessions) of this blinded stimulation.

    Device: Sham HD-tDCS sessions

  • Experimental
    Real stimulation - post randomized treatment

    Participants that agree to this will have up to 26 weeks of additional HD-tDCS sessions at home or in-person.

    Device: HD-tDCS sessions - Open-label (after randomized treatment)

Interventions

  • DeviceHD-tDCS sessions

    This project translates decades of observational neuroimaging research into a biologically plausible stimulation target (i.e., DAN) and uses functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) to plan personalized brain stimulation and to ensure target engagement. When available; those not MRI compatible will receive a standard montage with per channel amplitudes of up to 5 milliamperes (mA) or a montage derived from other imaging methods. Participants will receive 4 days of HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.

  • DeviceSham HD-tDCS sessions

    Participants will receive 4 days of sham HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.

  • DeviceHD-tDCS sessions - Open-label (after randomized treatment)

    Optional 26 weeks of additional HD-tDCS sessions. Participants can complete up to 5 days per week, but most people will complete about 3 days per week. The study team may also collect audio recordings of these sessions. Participants can complete this in person or at-home via using a secure, HIPAA-compliant videoconferencing with the supervision of a research staff member. Participant's that decide to complete the additional sessions at home, a research staff member will train a study partner during the first 4 HD-tDCS sessions in the office. This option may not be available or appropriate for all participants and the study team member will discuss this with participant's and study partners.

06

What researchers measure

Primary outcomes

  1. Change in network connectivity measured via fMRI

    Functional connectivity measures whether activity in different brain regions show similar patterns of change over time. Graph theory metrics of resting-state fMRI can characterize functional connectivity within the Dorsal Attention Network (DAN).

    Time frame: Baseline and Day 5 (after 4 days of HD-tDCS)

  2. Measure of form coherence

    This will evaluate dorsal and ventral visual stream functioning using a visual paradigm.

    Time frame: Baseline and at end of study intervention (up to 6 months)

  3. Long-term change in network connectivity via fMRI

    Functional connectivity measures whether activity in different brain regions show similar patterns of change over time. Graph theory metrics of resting-state fMRI can characterize functional connectivity within the Dorsal Attention Network.

    Time frame: Baseline and end of study intervention (up to 6 months)

  4. Measures of motion tasks

    This will evaluate dorsal and ventral visual stream function. Motion coherence is measured using a visual paradigm.

    Time frame: Baseline and at end of study intervention (up to 6 months)

Secondary outcomes

  1. Measures of motion tasks

    This will evaluate dorsal and ventral visual stream function. Motion coherence is measured using a visual paradigm.

    Time frame: Baseline and day 5 (after 4 days of HD-tDCS)

  2. Measure of form coherence tasks

    Form coherence is measured using a visual paradigm.

    Time frame: Baseline and day 5 (after 4 days of HD-tDCS)

  3. Eye tracking - Number of fixations

    The study team will quantify the number and duration of fixations, while the participants perform visual search, reading, or other visual tasks affected by PCA.

    Time frame: Baseline and at end of study intervention (up to 6 months)

  4. Eye tracking - Number of fixations

    The study team will quantify the number and duration of fixations, while the participants perform visual search, reading, or other visual tasks affected by PCA.

    Time frame: Baseline and day 5 (after 4 days of HD-tDCS)

  5. Self-ratings of cognitive change using the Posterior Cortical Atrophy Questionnaire (PCA-Q)

    The PCA-Q has 32 items and measures cognitive difficulty in 12 domains. It is reported as a composite score, with a lower overall score demonstrating less cognitive impairment.

    Time frame: Baseline and day 5 (after 4 days of HD-tDCS)

  6. Self-ratings of cognitive change using the Posterior Cortical Atrophy Questionnaire (PCA-Q)

    The PCA-Q has 32 items and measures cognitive difficulty in 12 domains. It is reported as a composite score, with a lower overall score demonstrating less cognitive impairment

    Time frame: Baseline and at end of study intervention (up to 6 months)

  7. Immersive virtual reality (IVR) path length

    Quotient of participants actual path length compared to the most efficient path length.

    Time frame: Baseline and at end of study intervention (up to 6 months)

  8. functional near infrared spectroscopy (fNIRS) - Activation magnitude of DAN (processed)

    Measured using standard fNIRS analysis

    Time frame: Baseline and at end of study intervention (up to 6 months)

  9. Partner rating of cognitive change using the PCA-Q

    The PCA-Q has 32 items and measures cognitive difficulty in 12 domains. It is reported as a composite score, with a lower overall score demonstrating less cognitive impairment

    Time frame: Baseline and day 5 (after 4 days of HD-tDCS)

  10. Partner rating of cognitive change using the PCA-Q

    The PCA-Q has 32 items and measures cognitive difficulty in 12 domains. It is reported as a composite score, with a lower overall score demonstrating less cognitive impairment

    Time frame: Baseline and at end of study intervention (up to 6 months)

07

Study locations

1 of 1 sites recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    • Stephen Schlaefflin, BS · Contact · schlst@umich.edu · 734-936-7360
    • Eileen Robinson, RN-BC · Contact · robinsoe@umich.edu · 734-763-1356
    • Benjamin Hampstead, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study data and documentation will be made available to the research community free of charge through the Deep Blue Data repository.

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07191327
Lead sponsor
University of Michigan
Responsible party
Benjamin Hampstead, PhD (Professor, University of Michigan) — Principal investigator
First posted
Sep 24, 2025
Start date
Jan 28, 2026
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jun 30, 2026

Study contacts

Stephen Schlaefflin, BS
Contact
schlst@umich.edu
734-936-7360
Eileen Robinson, RN-BC
Contact
robinsoe@umich.edu
734-763-1356
Benjamin Hamstead, PhD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion